yttrium/סרטן השד

הקישור נשמר בלוח

בחר סוג מיון

עמוד 1 מ 91 תוצאות

Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

BrE-3 is a murine IgG1 monoclonal antibody that binds to 97% of human ductal breast cancer specimens. A previous study documented the ability of 111In-labeled 1,4-methyl-benzyl isothiocyanate diethylenetriamine pentaacetic acid (111In-MX-DTPA) BrE-3 to specifically target breast cancer tissue in

Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Liver metastases secondary to breast cancer are associated with unfavourable prognosis. Radioembolization with ytrrium-90 is an emerging option for management of liver metastases of breast cancer when other systemic therapies have failed to achieve disease control. However, unlike the

Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

BACKGROUND Radioimmunotherapy (RIT) using 131I-Chimeric L6 (ChL6) antibody has shown therapeutic promise for patients with breast cancer. To enhance this potential, a novel immunoconjugate was developed that targets adenocarcinomas like breast cancer and tightly binds yttrium-90 (90Y) for therapy

Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE Therapy for patients with unresectable liver metastases from breast cancer that were refractory to multiple treatment regimens was performed using radioactive microspheres. High doses of radiation were delivered to tumors from these permanently implanted yttrium-90 ((90)Y) microspheres,

Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

BACKGROUND There are a paucity of data on the treatment of unresectable, chemoresistant breast cancer liver metastases (BRCLM) with yttrium-90 (Y90) radioembolization. METHODS Forty patients underwent resin-based Y90 radioembolization for unresectable, chemoresistant BRCLM between 2006 and 2012 in a

Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE To determine, in an open-label, retrospective report, the safety and effectiveness of locoregional therapy with yttrium-90 ((90)Y) radioembolization for patients with progressing breast cancer liver metastases (BCLMs) despite multi-agent chemotherapy. METHODS Seventy-five patients with

High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE Although radioimmunotherapy alone is effective in lymphoma, its application to solid tumors will likely require a combined modality approach. In these phase I studies, paclitaxel was combined with radioimmunotherapy in patients with metastatic hormone-refractory prostate cancer or advanced

Impressive Response to Concomitant Platinum-based Chemotherapy and Yttrium-90 in a Patient with Heavily Pretreated Triple-negative Breast Cancer Widely Metastasized to the Liver.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Metastatic triple-negative breast cancer (TNBC) constitutes a heterogeneous group of diseases with systemic treatment options limited to cytotoxic chemotherapy at the time being. The disease tends to affect visceral organs more frequently when compared to hormone receptor-positive breast cancer. The

[The efficacy of radiohypophysectomy with yttrium 90 in metastatic breast cancer (author's transl)].

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Radiohypophysectomy in 176 women with metastatic breast cancer, treated over the past 20 years, did not prolong life, but relieved pain in almost half of the patients. This procedure can be carried out quickly and without risk even in severly debilitated patients.

Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Radioimmunotherapy (RIT) in breast cancer patients using I-131-chimeric L6 (ChL6) and in human breast cancer xenografts in nude mice using Y-90-1,4,7,10-tetraazacylododecant N,N',N",N"'-tetraacetic acid-peptide ChL6 (Y-90-ChL6) has shown promise. Tumor cell response to low-dose rate (5-25 rads/h)

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Synergistic multimodality therapy is needed for breast cancer. Breast cancer frequently has p53 mutations that result in cells less likely to undergo apoptosis when exposed to DNA damaging therapies. Taxol (paclitaxel) is more effective in the presence of mutant p53. (90)Y-labeled DOTA-peptide-ChL6

Metastatic breast cancer in a 54-year-old woman: integrative treatment with yttrium-90 radioembolization.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

In 1993, a 54-year-old woman was diagnosed with early-stage breast adenocarcinoma and treated with doxorubicin and cyclophosphamide followed by tamoxifen. Nine years later, the patient presented for integrative treatment, with liver metastases. Carcinoembryonic antigen was significantly elevated.

Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

The novel radioimmunoconjugate, 90Y-DOTA-peptide-chimeric L6 (ChL6), was designed to reduce radiation to critical normal tissues with an exceptionally stable 90Y chelate moiety and a biodegradable linker. Human breast cancer tumors (HBT 3477) in mice were treated with 90Y-DOTA-peptide-ChL6 to

Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

cT84.66 is a human/murine IgG1 with high affinity and specificity for carcinoembryonic antigen (CEA). An earlier Phase I trial defined the maximum tolerated dose for 90Y-diethylenetriaminepentaacetic acid (DTPA)-cT84.66 at 22 mCi/m2. Dose-limiting toxicities were reversible leukopenia and

Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

To determine predictors of survival after transarterial radioembolization of hepatic metastases from breast cancer.Twenty-four patients with chemotherapy-refractory hepatic metastases from breast cancer who underwent radioembolization from 2013 to 2018 were

קודם
1
2
3
4
5
6
7
הַבָּא

הצטרפו לדף הפייסבוק שלנו

Herbal & Natural Medicine

המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע

עובד ב 55 שפות
מרפא צמחי מרפא מגובה על ידי מדע
זיהוי עשבי תיבול על ידי דימוי
מפת GPS אינטראקטיבית - תייגו עשבי תיבול במיקום (בקרוב)
קרא פרסומים מדעיים הקשורים לחיפוש שלך
חפש עשבי מרפא על פי השפעותיהם
ארגן את תחומי העניין שלך והתעדכן במחקר החדשות, הניסויים הקליניים והפטנטים

הקלד סימפטום או מחלה וקרא על צמחי מרפא שעשויים לעזור, הקלד עשב וראה מחלות ותסמינים שהוא משמש נגד.
* כל המידע מבוסס על מחקר מדעי שפורסם